The translation of drug efficacy from in vivo models to human disease with special reference to experimental autoimmune encephalomyelitis and multiple sclerosis

Inflammopharmacology

Volumn 15, Issue 5, 2007, Pages 183-187

  Bolton, C ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Drugs; Efficacy; Experimental Autoimmune Encephalomyelitis; Multiple Sclerosis

Indexed keywords

CORTICOSTERONE; DEXAMETHASONE; GLATIRAMER; HYDROCORTISONE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; PREDNISONE;

ALLERGIC ENCEPHALOMYELITIS; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; IN VIVO STUDY; MODEL; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 35348954386     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-007-1607-z     Document Type: Review

References (61)

1. Alderson, P., Roberts, I. (2005). Corticosteroids for acute traumatic brain injury. Cochrane Database Syst Rev, Jan25(1)CD000196.
2. Baker, D., O'Neill, J.K., Gschmeissner, S.E. et al. (1990). Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol, 28: 261-270.
3. Baker, D., Pryce, G., Croxford, J.L. et al. (2000). Cannabinoids control spasticity and tremor in a model of multiple sclerosis. Nature, 404: 84-87.
4. Baker, D., Pryce, G., Croxford, J.L. et al. (2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J, 15: 300-302.
5. Baker, D., Jackson, S.J. (2007). Models of multiple sclerosis. Adv Clin Neurosci Rehab, 6: 10-12.
6. Bifulco, M., Laezza, C., Malfitano, A.M. (2007). From anecdotal evidence of cannabinoids in multiple sclerosis to emerging new therapeutical approaches. Mult Scler, 13: 133-134.
7. Bolton, C., Allsopp, G., Cuzner, M.L. (1982). The effect of cyclosporin A on the adoptive transfer of experimental allergic encephalomyelitis in the Lewis rat. Clin Exp Immunol, 47: 127-132.
8. Bolton, C., Flower, R.J. (1989). The effects of the anti-glucocorticoid RU 38486 on steroid-mediated suppression of experimental allergic encephalomyelitis (EAE) in the Lewis rat. Life Sci, 45: 97-104.
9. Bolton, C. (1997). Neurovascular damage in experimental allergic encephalomyelitis: a target for pharmacological control. Med Inflam, 6: 295-302.
10. Bolton, C., O'Neill, J.K. Allen, S.J. et al. (1997). Regulation of chronic relapsing experimental allergic encephalomyelitis by endogenous and exogenous glucocorticoids. In Arch Allergy Immunol, 114: 74-80.
11. Bolton, C. and Paul, C. (2006). Glutamate receptors in neuroinflammatory demyelinating disease. Med Inlfam, 2006: 1-12.
12. Fischer, J.S., Rudick, R.A., Cutter, GR. et al. (1999). The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. Mult Scler, 5: 244-250.
13. Friese, M. A., Montalban, X., Wilcox, N. et al.. (2006). The value of animal models for drug development in multiple sclerosis. Brain, 129: 1940-1952.
14. Gaillard, P.J., van der Meide, P.H., de Boer, A.G. et al. (2001). Glucocorticoid and type 1 interferon interactions at the blood-brain barrier: relevance for drug therapies for multiple sclerosis. Neuroreport, 12: 2189-2193.
15. Giles, J. (2006). Animal experiments under fire for poor design. Nature, 444: 981.
16. Gold, R., Linington, C., Lassmann, H. (2006). Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain, 129: 1953-1071.
17. Groom, A.J., Smith, T., Turski, L. (2003). Multiple sclerosis and glutamate. Ann N Y Acad Sci 993: 229-275.
18. Johnson, K.P., Brooks, B.R., Cohen, J. A. et al. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology, 45: 1268-1276.
19. Komark, A., Dietrich, F.M. (1971). Chemical prevention of experimental allergic encephalomyelitis (EAE). Arch Int Pharmacodyn, 193: 249-257.
20. Kurtzke, J.F. (1983). Rating neurological impairment in multiple sclerosis: an expanded Disability Status Scale (EDSS). Neurology, 33: 1444-1452.
21. Levine, S., Sowinski, R. (1977). Suppression of the hyperacute form of experimental allergic encephalomyelitis by drugs. Arch Int Pharmacodyn, 230: 309-318.
22. Levine, S., Sowinski, R. (1980). Therapy of allergic encephalomyelitis in rats after onset of paralysis, in: The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis, Davison, A.N. and Cuzner, M.L. (Eds), pp. 199-209. Academic Press, London, UK.
23. Lublin, F.D., Lavasa, M., Viti, C. et al.. (1987). Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol, 45: 122-128.
24. Lublin, F.D. (2002). Therapeutic approaches to secondary progressive multiple sclerosis. Mult Scler, 8: 88-90.
25. McDevitt, H.O., Sela, M. (1965). Genetic control of the antibody response. I. Demonstration of determinant-specific differences in response to synthetic polypeptide antigens in two strains of inbred mice. J Exp Med, 122: 517-531.
26. b mice-fine specificity and T-cell receptor V expression of encephalitogen T-cells. Eur J Immunol, 25: 1951-1959.
27. Milligan, N.M., Newcombe, R., Compston, D.A. (1987). A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry, 50: 511-516.
28. Paterson, P.Y. (1976). Experimental autoimmune (allergic) encephalomyelitis: induction, pathogenesis, suppression, in: Textbook of Immunopathology, Meischer, P.A., Muller-Eberhard, H.J. (Eds) pp.179-213. Grune & Stratton, New York.
29. Paul, C. Bolton, C. (1995). Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-term therapy with dexamethasone or cyclosporin A. Int J Imunopharmacol, 17: 497-503.
30. Paul, C. and Bolton, C. (2002). Modulation of blood-brain barrier dysfunction and neurological deficits during acute experimental allergic encephalomyelitis by the N-methyl-D-aspartate antagonist memantine. J Pharmacol Exp Therap 302: 50-57.
31. Perel, P., Roberts, I., Sena, E. et al. (2007). Comparison of treatment effects between animal experiments and clinical trials: systemic review. BMJ, 334:197.
32. Perras, C. (2005). Sativex for the management of multiple sclerosis symptoms. Issues Emerg Health Technol, 72: 1-4.
33. Pitt, D., Werner, P., Raine, C.S. (2000). Glutamate excitotoxicity in a model of multiple sclerosis. Nature Med 6: 67-70.
34. Polman, C.H., O'Connor, P.W., Havrdova, E. et al. (2006). A randomised, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Eng J Med, 354: 899-910.
35. Provinciali, L., Ceravolo, M.G., Bartolini, M.et al. (1999). A multidimensional assessment of multiple sclerosis: relationship between disability domains. Acta Neurol Scand, 100: 156-162.
36. Ransohoff, R. M. (2006). EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trds Immunol, 27: 167-168.
37. Ridge, S.C., Sloboda, A.E., McReynolds, R. A. et al. (1985). Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol, 35: 35-42.
38. Roep, B. O., Atkinson, M., von Herrath, M. (2004). Satisfaction (not) guaranteed: re-evaluating the use of animal models of type 1 diabetes. Nat Rev Immunol, 4: 989-997.
39. Rosenthale, M.E., Datko, L.J., Kassarich, J. et al. (1969). Chemotherapy of experimental allergic encephalomyelitis. Arch Int Pharmacodyn, 179: 251-275.
40. Roxburgh, R. H. S. R., Seaman, S. R., Masterman, T. et al. (2005). Multiple sclerosis severity score. Using disability and disease duration to rate disease severity. Neurol, 64: 1144-1151.
41. Rudick, R.A., Stuart, W.H., Calabresi, P.A. et al. (2006). Natalizumab plus interferon β-1 for relapsing multiple sclerosis. N Engl J Med, 354: 911-923.
42. Satoh, J., Sakai, K., Endoh, M. et al. (1987). Experimental allergic encephalomyelitis mediated by murine encephalitogenic T cell lines specific for myelin proteolipid apoprotein. J Immunol, 138: 179-184.
43. Scott, L.J., Figgitt, D.P. (2004). Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs, 18: 379-396.
44. Sellebjerg, F., Frederiksen, J.L., Nielsen, P.M. et al. (1998). Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology, 51: 529-534.
45. Smith, T., Groom, A.J., Zhu B. et al. (2000). Autoimmune encephalomyelitis ameliorated by AMPA antagonists. Nat Med 6: 62-66.
46. Sriram, S., Steiner, I. (2005). Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol, 58: 939-945.
47. Solka, J.S., Stefanelli, M. (2005). The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler, 11: 425-432.
48. Steinman, L. (2005). Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov, 4: 510-519.
49. Steinman, L., Zamvil, S. S. (2006). How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol, 60: 12-21.
50. Strupp, M. (2005). The bioavailabilityof IV methylpredisolone and oral prednisone in multiple sclerosis. Neurology, 64: 1100.
51. Teitelbaum, D., Meshorer, A., Hirshfeld, T. et al. (1971). Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol, 1: 242-248.
52. Teitelbaum, D., Webb, C., Meshorer, A. et al. (1973). Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol, 3: 273-279.
53. Teitelbaum, D., Webb, C., Bree, M. et al. (1974). Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol, 3: 256-262.
54. 't Hart, B. A., van Meurs, M., Brok, H. P. M. et al. (2000). A new primate model for multiple sclerosis in the common marmoset. Immunol Today, 21: 290-297.
55. Vaney, C. Heinzel-Gutenbrunner, M., Jobin, P. et al. (2004). Efficacy, safety, and tolerability, of an orally administred cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomised, double-blind, placebo-controlled, crossover study. Mult Scler, 10: 417-424.
56. Virley, D. J. (2005). Developing therapeutics for the treatment of multiple sclerosis. NeuroRx, 2: 638-649.
57. Wade, D.T., Makela, P. Robson, P. et al. (2004). Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler, 10: 434-441.
58. Wade, D.T., Makela, P.M., House, H. et al. (2006). Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler, 12: 639-645.
59. Wallstrom, E., Diener, P., Ljungdahl, A. et al. (1996). Memantine abrogates neurological deficits, but not CNS inflammation, in Lewis rat experimental autoimmune encephalomyelitis. J Neurol Sci 137: 89-96.
60. Watson, C.M., Davison, A.N., Baker, D. et al. (1991). Suppression of demyelination by mitoxantrone. Int J Immunopharmacol, 13: 923-930.
61. Yednock, T., Cannon, C., Fritz, L.C. et al. (1992). Prevention of experimental autoimmune encephalomyelitis by antibodies against α4β1 integrin. Nature, 35: 63-66.